ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
106,580.36
3.36%
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs Yen
156.38
0.04%
Brent Oil
80.085
-0.16%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. EyePoint Pharmaceuticals Inc (EYPT)

  7. EyePoint Pharmaceuticals Inc (EYPT) ニュース

EYPT

EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:EYPT
日付受信時刻ニュースソース見出しコード企業名
2025/01/1621 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/1321 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/1321 : 00GlobeNewswire Inc.EyePoint Provides Company Update and Anticipated Development Milestones for 2025NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/0906 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/0906 : 11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/0821 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/0821 : 00GlobeNewswire Inc.EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of DirectorsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/0806 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/0806 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/0806 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/0806 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2025/01/0806 : 03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/12/1721 : 00GlobeNewswire Inc.EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/12/1621 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/12/0421 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/12/0421 : 00GlobeNewswire Inc.EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular DegenerationNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/11/1821 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/11/1505 : 10Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/11/0806 : 05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/11/0721 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/11/0721 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/11/0421 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/11/0105 : 16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/11/0105 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/10/3105 : 20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/10/3010 : 47GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Pricing of Upsized Public OfferingNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/10/2906 : 17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/10/2906 : 14GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Proposed Public Offering of Common StockNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/10/2820 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/10/2820 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular EdemaNASDAQ:EYPTEyePoint Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EYPT

最近閲覧した銘柄

BIT
S32597
Societe Generale Effekten
BIT
P1K879
BNP Paribas Issuance
BIT
P1SAX5
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有